Drug Profile
PF 6648671
Alternative Names: PF-06648671; PF-6648671Latest Information Update: 08 Mar 2018
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antidementias
- Mechanism of Action Amyloid precursor protein secretase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 30 Jan 2018 Discontinued - Phase-I for Alzheimer's disease (In volunteers) in Belgium and USA (PO) (Pfizer pipeline, March 2018)
- 28 Jan 2018 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in Belgium (PO, Suspension)
- 24 Aug 2017 Pharmacokinetic results from three phase I clinical trials in Healthy volunteers presented at the Alzheimer's Association International Conference 2017 (AAIC-2017)